Payment overview · 2025
General Payments
$940.33
47 reported records · 15 companies
Healthcare provider profile · identity verified
Ashley Chan, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · NEW ORLEANS, LA · NPI 1457764938
Verified facts
What the public records show
CMS Open Payments records show Ashley Chan, PA-C received $940.33 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.37 | 20.9% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.08 | 14.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $100.08 | 10.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.18 | 10.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $87.27 | 9.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.98 | 7.3% | 4 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $43.14 | 4.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.64 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.38 | 4.1% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $24.88 | 2.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.02 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.07 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.10 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.15 | 1.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.99 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $940.33 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $111.96 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $97.18 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $97.18 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.15 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $84.85 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $84.85 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $84.85 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.70 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.98 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.98 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.22 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $63.60 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $62.45 | 3 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $43.14 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.64 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 109 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 103 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 11 |
| Carvedilol | Carvedilol | 45 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Omeprazole | Omeprazole | 39 | suppressed |
| Losartan Potassium | Losartan Potassium | 37 | suppressed |
| Alprazolam | Alprazolam | 33 | 22 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 17 |
| Methylprednisolone | Methylprednisolone | 31 | 31 |
| Olanzapine | Olanzapine | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 30 |
| Lactulose | Lactulose | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 14 |
| Metformin Hcl | Metformin Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Lisinopril | Lisinopril | 26 | suppressed |
| Gabapentin | Gabapentin | 25 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | 15 |
| Risperidone | Risperidone | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 15 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 19 | 14 |
| Simvastatin | Simvastatin | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 15 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Prednisone | Prednisone | 17 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lamivudine Hbv | Lamivudine | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $940.33 · 47 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, APRETUDE, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EGRIFTA, FARXIGA, FREESTYLE LIBRE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PIFELTRO, PREVNAR 20, QULIPTA, SHINGRIX, TROGARZO, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XYOSTED, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error